Literature DB >> 8299647

Antibody-guided scintigraphy: targeting of the "magic bullet".

F Fazio1, G Paganelli.   

Abstract

Mesh：

Year:  1993        PMID： 8299647     DOI： 10.1007/BF00171010

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


× No keyword cloud information.
  27 in total

1.  The zone of activity of antibodies as determined by the use of radioactive tracers; the zone of activity of nephritoxic antikidney serum.

Authors:  D PRESSMAN; G KEIGHLEY
Journal:  J Immunol       Date:  1948-06       Impact factor: 5.422

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  Intraperitoneally administered 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: problems encountered and possible solutions.

Authors:  V Hird; J S Stewart; D Snook; B Dhokia; C Coulter; H E Lambert; W P Mason; W P Soutter; A A Epenetos
Journal:  Br J Cancer Suppl       Date:  1990-07

4.  Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours.

Authors:  A A Epenetos; K E Britton; S Mather; J Shepherd; M Granowska; J Taylor-Papadimitriou; C C Nimmon; H Durbin; L R Hawkins; J S Malpas; W F Bodmer
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

5.  A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.

Authors:  K Fujimori; D G Covell; J E Fletcher; J N Weinstein
Journal:  J Nucl Med       Date:  1990-07       Impact factor: 10.057

6.  Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients.

Authors:  G Paganelli; P Magnani; F Zito; E Villa; F Sudati; L Lopalco; C Rossetti; M Malcovati; F Chiolerio; E Seccamani
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

7.  Imaging of melanoma with L-131-labeled monoclonal antibodies.

Authors:  S M Larson; J P Brown; P W Wright; J A Carrasquillo; I Hellström; K E Hellström
Journal:  J Nucl Med       Date:  1983-02       Impact factor: 10.057

8.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.

Authors:  D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

9.  An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier".

Authors:  W van Osdol; K Fujimori; J N Weinstein
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

10.  A brief guide to the practice of radioimmunoscintigraphy and radioimmunotherapy in cancer. Report of the European Association of Nuclear Medicine Task Group on the clinical utility of labelled antibodies.

Authors:  K E Britton; G L Buraggi; R Bares; A Bischof-Delaloye; U Buell; D Emrich; M Granowska
Journal:  Int J Biol Markers       Date:  1989 Apr-Jun       Impact factor: 3.248
View more
  3 in total

1.  Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model.

Authors:  Takahito Nakajima; Kohei Sano; Peter L Choyke; Hisataka Kobayashi
Journal:  Theranostics       Date:  2013-04-23       Impact factor: 11.556

2.  Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma.

Authors:  P Magnani; G Paganelli; C Songini; A Samuel; F Sudati; A G Siccardi; F Fazio
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

3.  Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity.

Authors:  M Chinol; P Casalini; M Maggiolo; S Canevari; E S Omodeo; P Caliceti; F M Veronese; M Cremonesi; F Chiolerio; E Nardone; A G Siccardi; G Paganelli
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.